DK3523315T3 - Inhibitor af glucocorticoidreceptor - Google Patents

Inhibitor af glucocorticoidreceptor Download PDF

Info

Publication number
DK3523315T3
DK3523315T3 DK17859300.0T DK17859300T DK3523315T3 DK 3523315 T3 DK3523315 T3 DK 3523315T3 DK 17859300 T DK17859300 T DK 17859300T DK 3523315 T3 DK3523315 T3 DK 3523315T3
Authority
DK
Denmark
Prior art keywords
glucocorticoid receptor
receptor inhibitor
inhibitor
glucocorticoid
receptor
Prior art date
Application number
DK17859300.0T
Other languages
English (en)
Inventor
Daqing Sun
Lawrence R Mcgee
Xiaohui Du
Liusheng Zhu
Xuelei Yan
Yosup Rew
Julio C Medina
Haiying Zhou
Minna Delarae Balbas
John Eksterowicz
Valeria R Fantin
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Application granted granted Critical
Publication of DK3523315T3 publication Critical patent/DK3523315T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005Ketals
    • C07J21/008Ketals at position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • C07J71/0015Oxiranes at position 9(11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK17859300.0T 2016-10-07 2017-10-06 Inhibitor af glucocorticoidreceptor DK3523315T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662405801P 2016-10-07 2016-10-07
US201762526331P 2017-06-28 2017-06-28
PCT/US2017/055660 WO2018068021A1 (en) 2016-10-07 2017-10-06 Inhibitors of glucocorticoid receptor

Publications (1)

Publication Number Publication Date
DK3523315T3 true DK3523315T3 (da) 2021-05-03

Family

ID=61832215

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17859300.0T DK3523315T3 (da) 2016-10-07 2017-10-06 Inhibitor af glucocorticoidreceptor

Country Status (20)

Country Link
US (5) US10472387B2 (da)
EP (2) EP3851444A1 (da)
JP (2) JP6801093B2 (da)
KR (2) KR102237916B1 (da)
CN (2) CN110099915A (da)
AU (3) AU2017339510B2 (da)
BR (1) BR112019006987B1 (da)
CA (1) CA3039636C (da)
DK (1) DK3523315T3 (da)
ES (1) ES2867853T3 (da)
HU (1) HUE054542T2 (da)
IL (2) IL265835B (da)
MX (2) MX2019004030A (da)
NZ (1) NZ753142A (da)
PL (1) PL3523315T3 (da)
PT (1) PT3523315T (da)
SG (1) SG11201903055UA (da)
SI (1) SI3523315T1 (da)
WO (1) WO2018068021A1 (da)
ZA (1) ZA202004440B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11124537B2 (en) 2015-12-23 2021-09-21 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CA3009525A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
PT3523315T (pt) 2016-10-07 2021-04-29 Oric Pharmaceuticals Inc Inibidor de recetor de glucocorticoide
EP3773515A4 (en) * 2018-04-11 2022-03-23 Oric Pharmaceuticals, Inc. SOLID FORMS AND FORMULATIONS COMPRISING A GLUCOCORTICOID RECEPTOR ANTAGONIST AND THEIR USES
WO2021163273A1 (en) * 2020-02-12 2021-08-19 Oric Pharmaceuticals, Inc. Uses of glucocorticoid receptor antagonists
US20230212215A1 (en) * 2020-05-08 2023-07-06 Trustees Of Dartmouth College Glucocorticoid receptor modulators
CN115915529A (zh) * 2021-09-30 2023-04-04 赛万特科技有限责任公司 发光控制方法、发光控制装置及发光装置
CN114230627B (zh) * 2021-12-31 2023-09-15 湖南新合新生物医药有限公司 一种倍他米松环氧水解物中间体的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
JP2785023B2 (ja) 1987-12-30 1998-08-13 ルセル―ユクラフ 17α位置を置換された17β―OH―19―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
JPH02188599A (ja) 1988-11-16 1990-07-24 Roussel Uclaf 3―ケト―デルタ―4,9―19―ノルステロイドから誘導される新物質及びそれらよりなる薬剤
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
FR2651435A1 (fr) 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
DE4018167A1 (de) * 1990-06-01 1991-12-05 Schering Ag Verfahren zur herstellung von 10(beta)-h-steroiden
DE4042007A1 (de) * 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
AU687088B2 (en) 1993-08-04 1998-02-19 Merck Sharp & Dohme B.V. Antiglucocorticoid steroids for the treatment of anxiety disorders
WO1995017192A1 (en) 1993-12-22 1995-06-29 The Salk Institute For Biological Studies Methods for reducing multidrug resistance
MX9603889A (es) 1995-02-02 1997-04-30 Schering Ag Antagonistas de progesterona para la produccion de agente farmaceuticos para el tratamiento de sangrado uterino disfuncional.
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
IL122740A (en) * 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
CN1085078C (zh) * 1998-01-07 2002-05-22 沈志华 用于大月份引产的复合药物
US6512130B1 (en) * 2000-09-05 2003-01-28 Council Of Scientific And Industrial Research Mifepristone analogue, process for the preparation thereof and use thereof
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
US7250408B2 (en) * 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
PL1989218T3 (pl) 2006-02-17 2010-06-30 Janssen Pharmaceutica Nv Pochodne 17-fosforosteroidów użyteczne jako modulatory receptora progesteronowego
SG170809A1 (en) 2006-03-29 2011-05-30 Univ California Diarylthiohydantoin compounds
PL2148681T3 (pl) 2007-04-20 2016-09-30 Selektywny modulator progesteronu w leczeniu krwawienia z macicy
EP2671086B1 (en) 2011-02-03 2018-04-25 Pop Test Oncology LLC System and method for diagnosis and treatment
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
US20130029953A1 (en) 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
US9289436B2 (en) 2012-02-24 2016-03-22 The University Of Chicago Method of treatment of prostate cancer with androgen receptor and glucocorticoid receptor antagonists
EP2641602A1 (en) 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
WO2015089338A2 (en) * 2013-12-11 2015-06-18 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CA3009525A1 (en) * 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11124537B2 (en) * 2015-12-23 2021-09-21 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
PT3523315T (pt) 2016-10-07 2021-04-29 Oric Pharmaceuticals Inc Inibidor de recetor de glucocorticoide
WO2018227129A1 (en) 2017-06-09 2018-12-13 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
EP3773515A4 (en) 2018-04-11 2022-03-23 Oric Pharmaceuticals, Inc. SOLID FORMS AND FORMULATIONS COMPRISING A GLUCOCORTICOID RECEPTOR ANTAGONIST AND THEIR USES

Also Published As

Publication number Publication date
JP6801093B2 (ja) 2020-12-16
US10723759B2 (en) 2020-07-28
MX2019004030A (es) 2019-09-16
US10472387B2 (en) 2019-11-12
PT3523315T (pt) 2021-04-29
AU2020213316A1 (en) 2020-08-27
US10836789B2 (en) 2020-11-17
SG11201903055UA (en) 2019-05-30
KR20190083651A (ko) 2019-07-12
ES2867853T3 (es) 2021-10-21
US20190218246A1 (en) 2019-07-18
AU2017339510B2 (en) 2020-07-30
US20230096870A1 (en) 2023-03-30
US20200055892A1 (en) 2020-02-20
CN110099915A (zh) 2019-08-06
AU2017339510A1 (en) 2019-05-23
JP2021046409A (ja) 2021-03-25
BR112019006987B1 (pt) 2021-05-04
EP3851444A1 (en) 2021-07-21
AU2021202016B2 (en) 2022-01-06
AU2020213316B2 (en) 2021-03-11
JP2019533651A (ja) 2019-11-21
PL3523315T3 (pl) 2021-10-18
SI3523315T1 (sl) 2021-08-31
EP3523315B1 (en) 2021-03-24
IL284005A (en) 2021-07-29
CA3039636A1 (en) 2018-04-12
US20200291058A1 (en) 2020-09-17
HUE054542T2 (hu) 2021-09-28
CA3039636C (en) 2023-04-11
NZ753142A (en) 2020-08-28
AU2021202016C1 (en) 2022-06-09
MX2021010252A (es) 2021-09-21
WO2018068021A1 (en) 2018-04-12
EP3523315A4 (en) 2020-04-15
IL265835B (en) 2021-06-30
CN111690031B (zh) 2021-06-01
CN111690031A (zh) 2020-09-22
ZA202004440B (en) 2022-07-27
KR102237916B1 (ko) 2021-04-09
KR20210039001A (ko) 2021-04-08
US20210017219A1 (en) 2021-01-21
IL265835A (en) 2019-06-30
AU2021202016A1 (en) 2021-04-29
EP3523315A1 (en) 2019-08-14
BR112019006987A2 (pt) 2019-06-25

Similar Documents

Publication Publication Date Title
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3473270T3 (da) Konjugat af antistof-lægemiddel
DK3300500T3 (da) Triazolagonister af apj-receptoren
DK3371171T3 (da) Inhibitorer af RET
DK3661921T3 (da) Selektive hæmmere af nlrp3-inflammasom
DK3523315T3 (da) Inhibitor af glucocorticoidreceptor
DK3280479T3 (da) Udvideligt hylster
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3442972T3 (da) Bromdomænehæmmere
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK3344805T3 (da) Fremgangsmåde til udvælgelse af aptamerer til ubundne mål
DK3368683T3 (da) Fremgangsmåde til kvantifikationen af pd-l1
DK3458100T3 (da) Selektiv reduktion af cystein-manipulerede antistoffer
DK3534709T3 (da) Substituerede sulfonylamider til bekæmpelse af skadedyr
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3529236T3 (da) Krystalformer af eravacyclin
DK2910535T3 (da) Sammensætning til anvendelse af ekspanderet perlit
DK3418273T3 (da) Derivater af flavagliner
DK3430004T3 (da) Faststofformer af nilotinibsalte
DK3467005T3 (da) Fremgangsmåde til opnåelse af bionedbrydeligt polyesteretheramid
DK3149422T3 (da) Anordning til fremstilling af cementklinker
DK3481826T3 (da) Tyrosinkinaseinhibitorer